The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B01 | Antithrombotic agents | |
| 3 | B01A | Antithrombotic agents | |
| 4 | B01AC | Platelet aggregation inhibitors excl. heparin | |
| 5 | B01AC04 | Clopidogrel |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 75 mg |
| Active Ingredient | Description | |
|---|---|---|
| Clopidogrel |
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CLOPIDOGREL ZENTIVA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CLOPIVAS Film-coated tablet | Web Search | MPI, US: SPL/PLR | |
| PLAVIX 75mg Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| PLAVIX Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ZYLLT Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
